Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State and Chairman of the Central Military Commission, awarded medals and medals to winners of the National Medal and National Honorary Titles and delivered important speeches.

Zhong Nanshan
Awarded
Medal of the Republic
Leading figures in the field of respiratory disease research in my country have the courage to speak up and take responsibility. The prevention and control strategies and measures proposed have saved countless lives and have made great contributions to the prevention and control of SARS and COVID-19.

Zhang Boli
Awarded
National honorary title of "People's Hero"
Instructing Chinese medicine to intervene in the treatment of new coronary pneumonia, presided over the research and formulation of integrated Chinese and Western medicine has become a highlight of China's plan, and has made a significant contribution to promoting the inheritance and innovation of Chinese medicine.

Zhang Dingyu
Awarded
National honorary title of "People's Hero"
An outstanding representative who has rooted in the front line of medical care, as a patient with progressive frost disease, during the epidemic, he still has no hesitation, charged forward, rescued the wounded, and made a significant contribution to winning the defense war in Hubei and Wuhan.

Chen Wei
Awarded
National honorary title of "People's Hero"
He has been engaged in research on the prevention and control of biological hazards for a long time. After the outbreak of the new crown pneumonia epidemic, he has made major achievements in basic research, vaccine and protective drug research and development, and has made major contributions to epidemic prevention and control.

The conference also commended the national advanced individual and advanced collective in the fight against the new crown pneumonia epidemic, the national outstanding communist party member, the national advanced grassroots party organization

What is the current progress of the recombinant new crown vaccine developed by the Chinese Academy of Military Sciences?
What are the characteristics of this vaccine?
After the successful phase III clinical trial, how long will it take to go public on a large scale?
Who is suitable for vaccination?
Does the vaccine have a preventive effect on the mutated new coronavirus?
What is the current position of my country's vaccine research and development in the world?

In response to these issues, a reporter from Xinhua News Agency recently interviewed Chen Wei, the winner of the national honorary title of "People's Hero", an academician of the Chinese Academy of Engineering, and a researcher at the Academy of Military Medicine of the Academy of Military Sciences.

"What are the characteristics of the recombinant new crown vaccine developed by the Academy of Military Sciences?"

Chen Wei: We have independent intellectual property rights for this vaccine, which means that we do not need to look at the faces of others to develop our vaccine at any time and on any occasion. When the subsequent vaccine is put into production and application, we can also let the Chinese people get the vaccination as soon as they need it at a lower price.

This is a technologically advanced virus vector vaccine. Its outstanding feature is that it can have both humoral immunity (antibody and neutralizing antibody) and cellular immunity. Since the virus is a parasite, it cannot grow or reproduce by itself. It needs to reproduce in human cells. Therefore, cellular immunity is essential for virus prevention and control. We launched the world's first phase I clinical trial on March 16, and published the phase I clinical trial data on the "Lancet" on May 22. All 108 people vaccinated developed antibodies. The editor-in-chief of "The Lancet" commented on this as "The vaccine is safe and well tolerated. It is the world's first clinical data. A single injection can quickly trigger immunity, which is an important milestone." In this process, we Testing methods and testing indicators have been announced to the world, so that scientific research colleagues in other countries will avoid some detours and speed up vaccine research.

On July 20th, we announced Phase II clinical data for the first time to the world. Phase I and Phase II clinical trials have proved the effectiveness and safety of the vaccine. In June, our vaccine has been vaccinated in specific populations.

Phase III clinical trials are currently being effectively advanced. As the domestic epidemic has been effectively controlled, we need to go abroad to advance Phase III clinical trials and conduct larger-scale vaccine effectiveness and safety evaluations.

"After the Phase III clinical trial is successful, how long will it take to go public on a large scale?"

Chen Wei: Generally speaking, the development of a vaccine has to go through phase three clinical trials, and the test results meet the relevant requirements before preparing for mass production. However, our recombinant COVID-19 vaccine has been prepared for large-scale mass production since the Phase I clinical trial. From the current point of view, the goal of annual output of 300 million is achievable, and we are working hard to expand production capacity. After the Phase III test results come out, our production capacity will also keep up, and we will be ready to vaccinate the people on a large scale at any time and strive for seamless integration.

"Which people do you think are suitable for priority vaccination?"

Chen Wei: First of all, people who are in direct contact with the new coronavirus or have the possibility of close contact, such as those closely related to epidemic prevention, especially front-line medical staff, virus-related researchers, and front-line customs staff. In addition, people with underlying diseases are also our focus. There are also people who are willing to vaccinate themselves.

Regarding the vaccination group and vaccination time, we only put forward opinions and suggestions, and the relevant departments make overall decisions. We mainly prepare high-quality vaccines and can use them in time when the country needs them. This is our responsibility.

"How long will the recombinant new crown vaccine provide effective protection after vaccination?"

Chen Wei: It has only been more than half a year since the new coronavirus was isolated. How long is the validity period of the vaccine? There will not be too many data in the world. It must be data within one year. Our vaccine entered the world's first phase I clinical trial in March, and we only have data within half a year. From the current point of view, the injection in March is still effective. How long can its protection last? We are still advancing related research. At present, we can only speculate based on similar vaccines in the past. For example, the Ebola vaccine will decrease its immune response after the first injection for six months. The second needle is enhanced and can be effective for two years. This is data that can be used as a reference.

"If the new coronavirus mutates, will the vaccine fail?"

Chen Wei: We are a genetically engineered vaccine. We just find the most useful gene and make it into a vaccine. Judging from the current data analysis, the probability of a change in the gene we selected is very low. Up to now, our recombinant new coronavirus vaccine can completely cover the mutated new coronavirus.

In addition, because we are genetically engineered vaccines, once mutations occur and the protective effect is affected, we can use the current vaccines as the basic immunity, and quickly build a more targeted vaccine to boost it, just like giving Software upgrades and patches are the same. This is also the reason why so many countries in the world are making genetic engineering vaccines-it is a new generation of technology and a sunrise technology that we need to vigorously develop in the future.

"What do you think of our country's new crown vaccine development process in the world?"

Chen Wei: There is no doubt that our country is in the first phalanx of the world's new crown vaccine research and development. We currently account for more than half of the vaccines announced by the WHO that have entered phase III clinical trials. This data is already very telling.

The Chinese bio-specific immunoglobulin made its first public appearance at the Service Trade Fair

At the 2020 China International Trade in Services Fair held in Beijing from September 5th to 9th, Sinopharm Sinopharm, which was invited to participate in the public health and epidemic prevention special exhibition area, presented two new inactivated vaccines for the new crown. The identity of "Main Coffee" made a stunning debut for the first time and attracted the attention of the audience.

　　 It is understood that the two COVID-19 inactivated vaccines exhibited at the exhibition have now entered the final phase III clinical trials, and are being carried out intensively in the UAE, Bahrain, Peru, Morocco, Argentina and other countries and regions. The enrolled 50,000 people were vaccinated, and the sample population has now covered 115 countries, and progress in all aspects is leading the world. At the same time, China National Biotech has established high-level biosafety production facilities in two biological products research institutes in Beijing and Wuhan, and the total annual production capacity of the two vaccine production workshops can reach 300 million doses.

In addition, China's bio-specific immunoglobulin, which has played an important role in the prevention and control of the epidemic in Hubei and Wuhan, as well as in the emergency treatment of critically ill patients in Beijing Xinfadi, Urumqi, Xinjiang, etc., is also in the service trade fair. Made its first public appearance on In the context of the continuous deterioration of the new crown pneumonia epidemic situation in many countries around the world, China's biotechnology anti-epidemic achievements have attracted attention.

The People's Liberation Army launched two missiles into the South China Sea yesterday (26th) morning, one of which is the Dongfeng 21D aircraft carrier killer anti-ship missile. This move is to warn the United States.

On Tuesday, the U.S. U-2 high-altitude reconnaissance plane once broke into the no-fly zone for live-fire exercises in the northern theater of the People's Liberation Army, prompting the Chinese Ministry of Defense to protest, saying that the United States was provoking. Yesterday the People's Liberation Army conducted a test-fire of anti-ship ballistic missiles in the South China Sea, and the US military dispatched reconnaissance planes to conduct reconnaissance.

The report pointed out that the PLA launched Dongfeng 26B and Dongfeng 21D missiles, intended to warn the United States. The two missiles were launched from Qinghai and Zhejiang, respectively, towards the sea between Hainan Province and the Paracel Islands.

Previously, the Hainan Maritime Safety Administration had announced that it would conduct military training in the waters southeast of Hainan Island from the 24th to the 29th, and both missiles fell into the exercise prohibited zone.

Science and Technology Daily, Beijing, August 25 (Intern Gao Xingjian) According to a recent report on the "Nature" website, through in vivo experiments on small laboratory animals, two groups of researchers in the United States and China have discovered that the infusion of candidate new crown vaccines in the nasal cavity can start To achieve the immune effect, and may be more effective than traditional injection vaccines, it is expected that after the vaccine is put into use, it can be provided to the public more efficiently, and its social benefits cannot be underestimated.

In order to implement the nasal vaccination experiment, a team from the University of Washington School of Medicine designed a candidate vaccine that can encode the spike protein of the new coronavirus. It is through this spike protein that the new coronavirus completes the infection process by binding to the host cell. The researchers injected the vaccine into mice that have the human receptor corresponding to the protein after bioengineering.

According to records and observations, after the injection of the vaccine, no infectious virus was found in the lungs of the mice exposed to the new coronavirus, but a small amount of viral RNA was indeed detected. In contrast, no viral RNA was detected in mice vaccinated nasally, combined with other evidence that nasal vaccination can achieve complete immunity.

At the same time, the research team of the First Affiliated Hospital of Guangzhou Medical University used another vaccine that encodes the spike protein of the new coronavirus to conduct experiments on rhesus monkeys. The researchers found that nasal vaccination is the same as traditional injection. Play the effect of preventing virus infection. At the end of the experiment, the trachea and bronchus of rhesus monkeys who received different doses of injection or nasal drops were sampled to detect viral nucleic acid at 9 sites, and the results were all negative. In contrast, monkeys that have not been vaccinated have detected high levels of virus in different locations.

The researchers said that the discovery of nasal vaccination methods can enable people to instill vaccines by themselves, which makes vaccination more convenient and easy. At the same time, the method of nasal immunization is expected to reduce the potential immune problems caused by the adenovirus vector itself and achieve better The immune effect.